IL32 and Myocardial fibrosis: Emerging biomarkers like IL-32, Dickkopf-related protein 1 (DKK-1), and galectin-3 also show potential in further refining risk assessment, particularly for atherosclerosis and myocardial fibrosis in rheumatic diseases.